Kodiak Sciences Inc. (KOD)
Data as of , from SEC Form 4 filings.
See up to 3 months of KOD. The 7-day demo opens the 1M and 3M ranges and puts KOD on your watchlist.
Start 7-day demoLatest KOD insider trades
About Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- PALO ALTO, CA
- 124
- 2018
- XNAS
KOD Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 30 | 807,840 | $58.63M |
| Grant or award | 2 | 166,500 | |
| Option exercise | 6 | 2,561,048 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
KOD insider transactions (Form 4)
7124 Form 4 filings on record, the earliest from Jun 30, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 856 | $61.21 footnote F1 | $52K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 14,344 | $61.21 footnote F1 | $878K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 2,666 | $61.63 footnote F6 | $164K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 44,690 | $61.63 footnote F6 | $2.75M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 243 | $62.96 footnote F7 | $15K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 4,067 | $62.96 footnote F7 | $256K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 479 | $64.43 footnote F8 | $31K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 8,021 | $64.43 footnote F8 | $517K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 321 | $67.10 footnote F9 | $22K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 5,382 | $67.10 footnote F9 | $361K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 154 | $68.37 footnote F10 | $11K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 2,585 | $68.37 footnote F10 | $177K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 2,331 | $68.96 footnote F11 | $161K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 39,066 | $68.96 footnote F11 | $2.69M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 1,056 | $71.48 footnote F12 | $75K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 17,698 | $71.48 footnote F12 | $1.27M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 16,641 | $72.39 footnote F13 | $1.20M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 278,978 | $72.39 footnote F13 | $20.19M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 4,696 | $73.08 footnote F14 | $343K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 78,726 | $73.08 footnote F14 | $5.75M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 4,577 | $73.97 footnote F15 | $339K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 76,723 | $73.97 footnote F15 | $5.68M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 1,924 | $75.52 footnote F16 | $145K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 32,261 | $75.52 footnote F16 | $2.44M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 3,681 | $76.35 footnote F17 | $281K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 61,700 | $76.35 footnote F17 | $4.71M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 2,884 | $77.43 footnote F18 | $223K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 48,350 | $77.43 footnote F18 | $3.74M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 2,969 | $78.57 footnote F19 | $233K | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | Common Stock | 49,771 | $78.57 footnote F19 | $3.91M | |
| ||||||
 Victor Perlroth - Officer | Option exercise | Common Stock | 600,000 | $5.38 | $3.23M | |
| Victor Perlroth - Officer | Option exercise | Common Stock | 365,840 | $2.49 | $911K | |
| Victor Perlroth - Officer | Option exercise | Common Stock | 314,684 | $3.95 | $1.24M | |
| Victor Perlroth - Officer | Option exercise | Stock Option (Right to Buy) | 600,000 | $0.00 | - | |
| Victor Perlroth - Officer | Option exercise | Stock Option (Right to Buy) | 365,840 | $0.00 | - | |
| Victor Perlroth - Officer | Option exercise | Stock Option (Right to Buy) | 314,684 | $0.00 | - | |
| John A. Borgeson - Officer | Grant or award | Stock Option (Right to Buy) | 66,500 | $0.00 | - | |
| Victor Perlroth - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
 Taiyin Yang | Grant or award | Stock Option (Right to Buy) | 17,731 | $0.00 | - | |
| Robert Profusek | Grant or award | Stock Option (Right to Buy) | 17,731 | $0.00 | - | |
| Richard S. Levy | Grant or award | Stock Option (Right to Buy) | 17,731 | $0.00 | - | |
 Bassil I. Dahiyat | Grant or award | Stock Option (Right to Buy) | 17,731 | $0.00 | - | |
 Charles A. Bancroft | Grant or award | Stock Option (Right to Buy) | 17,731 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Options (right to buy) | 17,731 footnote F1 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Options (right to buy) | 17,731 footnote F1 | $0.00 | - | |
| ||||||
| John A. Borgeson - Officer | Option exercise | Common Stock | 30,000 | $1.04 | $31K | |
| John A. Borgeson - Officer | Open-market sale | Common Stock | 25,896 | $34.01 footnote F2 | $881K | |
| John A. Borgeson - Officer | Open-market sale | Common Stock | 4,104 | $34.67 footnote F3 | $142K | |
| John A. Borgeson - Officer | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| ||||||
| John A. Borgeson - Officer | Option exercise | Common Stock | 28,614 | $1.04 | $30K | |
| John A. Borgeson - Officer | Option exercise | Stock Option (Right to Buy) | 28,614 | $0.00 | - | |
| John A. Borgeson - Officer | Option exercise | Common Stock | 30,000 | $1.04 | $31K | |
| John A. Borgeson - Officer | Open-market sale | Common Stock | 12,692 | $39.14 footnote F2 | $497K | |
| John A. Borgeson - Officer | Open-market sale | Common Stock | 12,477 | $40.29 footnote F3 | $503K | |
| John A. Borgeson - Officer | Open-market sale | Common Stock | 4,231 | $40.88 footnote F4 | $173K | |
| John A. Borgeson - Officer | Open-market sale | Common Stock | 600 | $41.77 footnote F5 | $25K | |
| John A. Borgeson - Officer | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| ||||||
| Victor Perlroth - Officer | Option exercise | Common Stock | 300,000 | $1.04 | $312K | |
| Victor Perlroth - Officer | Option exercise | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Victor Perlroth - Officer | Grant or award | Stock Option (Right to Buy) | 175,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 217,428 footnote F1 | $23.00 | $5.00M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,391,268 footnote F1 | $23.00 | $55.00M | |
| ||||||
| John A. Borgeson - Officer | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Victor Perlroth - Officer | Grant or award | Stock Option (Right to Buy) | 340,000 | $0.00 | - | |
| Charles A. Bancroft | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Bassil I. Dahiyat | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Richard S. Levy | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Taiyin Yang | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Robert Profusek | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Options (right to buy) | 40,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Options (right to buy) | 40,000 | $0.00 | - | |
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
Recent KOD Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
KOD insider trading FAQ
What is the latest insider trade for KOD?
Kodiak Sciences Inc. (KOD) had 4 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for KOD runs to 24 Form 4 filings, the earliest from 2025-06-30. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying KOD stock?
30 insider purchases of KOD were filed in the last 90 days, totaling $58.63M.
How many insiders are selling KOD stock?
No insider sales of KOD were filed in the last 90 days. 6 sales are on record for this company.
Where can I see KOD SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects KOD Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - BAKER BROS. ADVISORS LP view on EDGAR
- - Victor Perlroth view on EDGAR
- - John A. Borgeson view on EDGAR
- - Victor Perlroth view on EDGAR
- - Taiyin Yang view on EDGAR
- - Robert Profusek view on EDGAR
- - Richard S. Levy view on EDGAR
- - Bassil I. Dahiyat view on EDGAR
- - Charles A. Bancroft view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where KOD's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow KOD with a 7-day demo
- KOD on your watchlist
- Every KOD Form 4 filing on record
- Up to 3 months of KOD price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
